Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Citations
1,777 citations
1,514 citations
743 citations
Cites background from "Phase II Trial of Bicalutamide in P..."
...Expressions of AR is observed in 30% of TNBC patients, and the AR inhibitor bicalutaminde showed a clinical benefit rate of 19% in ER/PR negative breast cancer patients in a phase II study [138,139]....
[...]
731 citations
Cites methods from "Phase II Trial of Bicalutamide in P..."
...performed antiandrogen therapy on LAR-subtype TNBC patients and found that this group of patients could benefit from antiandrogen treatment [56]....
[...]
...Although the CBR of immune checkpoint inhibitors targeting PD-L1/PD-1 was relatively low, some patients had a good prognosis and significantly increased OS rates....
[...]
...A phase II clinical trial using bicalutamide, a targeted AR inhibitor, for the treatment of breast cancer patients with positive AR and negative ER and PR expression showed a 19% clinical benefit rate (CBR) [56]....
[...]
...A phase II clinical trial using bicalutamide, a targeted AR inhibitor, for the treatment of breast cancer patients with positive AR and negative ER and PR expression showed a 19% clinical benefit rate (CBR) [56]....
[...]
...Traina et al. obtained a 25% CBR by using enzalutamide, an AR inhibitor, to treat AR-positive TNBC patients [57]....
[...]
676 citations
References
10,630 citations
4,215 citations
"Phase II Trial of Bicalutamide in P..." refers background in this paper
...which is defined as luminal AR and marked by hormoneregulated pathways with expression of higher levels of AR mRNA than the other subtypes (6)....
[...]
...The full potential of targeting AR in both ER( ) and ER(þ) breast cancers is not yet explored, and the possibility of dual pathway inhibition of androgen and HER2, MEK, or PI3K/AKT as suggested by preclinical trials is unexplored clinically (6, 27, 28, 34, 35)....
[...]
3,945 citations
"Phase II Trial of Bicalutamide in P..." refers background in this paper
...Eight patients whose tumors tested ARþ were ineligible for treatment due to testing ER(þ) centrally (2), developing a second primary cancer (1), not meeting all of the prespecified eligibility criteria (2), or having a significant decline in performance status (3)....
[...]
3,902 citations
2,562 citations
"Phase II Trial of Bicalutamide in P..." refers methods in this paper
...Cytokeratin-5/6 and EGF receptor (EGFR) were tested to apply Nielsen criteria as a surrogate for basal-like breast cancer (12)....
[...]